Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Orange Book Transparency Act of 2020
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act.
Orange Book Transparency Act of 2020
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2019 · fourth_quarter · 4A
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Filing targets: HOUSE OF REPRESENTATIVES
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2019 · fourth_quarter · Q4
Source: Senate LDA
Orange Book Transparency Act of 2020
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act.
Orange Book Transparency Act of 2020
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Orange Book Transparency Act of 2020
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Further Extension of Continuing Appropriations Act, 2021
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act.
Further Extension of Continuing Appropriations Act, 2021
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Further Extension of Continuing Appropriations Act, 2021
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act.
Further Extension of Continuing Appropriations Act, 2021
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Further Extension of Continuing Appropriations Act, 2021
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Prescription Drug STAR Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act.
Prescription Drug STAR Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Prescription Drug STAR Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act.
Prescription Drug STAR Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Prescription Drug STAR Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes.
Client: 340B HEALTH · Firm: WAXMAN STRATEGIES
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes.
Client: 340B HEALTH · Firm: WAXMAN STRATEGIES
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes.
Client: 340B HEALTH · Firm: WAXMAN STRATEGIES
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes.
Client: 340B HEALTH · Firm: WAXMAN STRATEGIES
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Issues impacting the 340B drug discount program; SERV Communities Act HR 6071
Issues impacting the 340B drug discount program; SERV Communities Act HR 6071
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Client: 340B HEALTH · Firm: WAXMAN STRATEGIES
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Client: 340B HEALTH · Firm: WAXMAN STRATEGIES
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Client: 340B HEALTH · Firm: WAXMAN STRATEGIES
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Client: 340B HEALTH · Firm: WAXMAN STRATEGIES
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Hatch-Waxman Integrity Act of 2018
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; Hatch-Waxman Integrity Act, S. 3738; S.974 - Creating and Restoring Equal Access to Equivalent Samples Act
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: GARY AND MARY WEST HEALTH INSTITUTE, INC · Firm: WAXMAN STRATEGIES
Issues impacting drug prices; Hatch-Waxman Integrity Act, S. 3738; S.974 - Creating and Restoring Equal Access to Equivalent Samples Act
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Filing targets: HOUSE OF REPRESENTATIVES
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2019 · third_quarter · Q3
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act; H.R 3 - Lower Drug Costs Now Act.
Filing targets: HOUSE OF REPRESENTATIVES
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2019 · second_quarter · Q2
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act.
Filing targets: HOUSE OF REPRESENTATIVES
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2019 · first_quarter · Q1
Issues impacting drug prices; H.R. 1503 - Orange Book Transparency Act; H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 2113 - Prescription Drug STAR Act.
Filing targets: HOUSE OF REPRESENTATIVES
340B HEALTH via WAXMAN STRATEGIES
2018 · fourth_quarter · Q4
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GARY AND MARY WEST HEALTH INSTITUTE, INC via WAXMAN STRATEGIES
2018 · fourth_quarter · Q4
Issues impacting drug prices; Hatch-Waxman Integrity Act, S. 3738; S.974 - Creating and Restoring Equal Access to Equivalent Samples Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICINES360 via WAXMAN STRATEGIES
2018 · third_quarter · Q3
Issues impacting the 340B drug discount program; SERV Communities Act HR 6071
Issues impacting the 340B drug discount program; SERV Communities Act HR 6071
Filing targets: HOUSE OF REPRESENTATIVES
340B HEALTH via WAXMAN STRATEGIES
2018 · third_quarter · Q3
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
Issues affecting the 340B drug pricing program; HR 6071 - SERV Communities Act; HR 4392 - To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; H.R.6157 - Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019
MEDICINES360 via WAXMAN STRATEGIES
2018 · second_quarter · Q2
Issues impacting the 340B drug discount program; Pause Act
Issues impacting the 340B drug discount program; Pause Act
Filing targets: HOUSE OF REPRESENTATIVES
340B HEALTH via WAXMAN STRATEGIES
2018 · second_quarter · Q2
Issues affecting the 340B drug pricing program; Pause Act
Issues affecting the 340B drug pricing program; Pause Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICINES360 via WAXMAN STRATEGIES
2018 · first_quarter · Q1
Issues impacting the 340B drug discount program; Pause Act
Issues impacting the 340B drug discount program; Pause Act
Filing targets: HOUSE OF REPRESENTATIVES
340B HEALTH via WAXMAN STRATEGIES
2018 · first_quarter · Q1
Issues affecting the 340B drug pricing program; Pause Act
Issues affecting the 340B drug pricing program; Pause Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICINES360 via WAXMAN STRATEGIES
2018 · first_quarter · RR
Issues related to the 340B drug discount program
Issues related to the 340B drug discount program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE